Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 9/20 | 0.69 |
| ▸ | MAP2K1 | Q02750 | 4/20 | 0.53 |
| ▸ | EGFR | P00533 | 9/20 | 0.52 |
| ▸ | ERBB2 | P04626 | 8/20 | 0.52 |
| ▸ | RAF1 | P04049 | 2/20 | 0.51 |
| ▸ | GAK | O14976 | 2/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.48 |
| ▸ | BCR | P11274 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22188261 | 0.86 | SRC (0.69) | SRCMAP2K1EGFRERBB2RAF1 | |
| SCHEMBL6379940 | 0.83 | SRC (0.67) | SRCMAP2K1EGFRERBB2RAF1 | |
| SCHEMBL14953424 | 0.75 | PDGFRB (0.68) | EGFR | |
| SCHEMBL29576652 | 0.75 | PDGFRB (0.68) | EGFR | |
| SCHEMBL20782589 | 0.73 | SRC (0.57) | SRCMAP2K1EGFRERBB2RAF1 | |
| SCHEMBL2747774 | 0.73 | SRC (0.57) | SRCMAP2K1RAF1ABL1 | |
| SCHEMBL5054175 | 0.73 | SRC (0.60) | SRCMAP2K1EGFRERBB2GAK | |
| SCHEMBL4743752 | 0.71 | SRC (0.62) | SRCMAP2K1EGFRERBB2GAK | |
| SCHEMBL20782450 | 0.71 | SRC (0.54) | SRCMAP2K1EGFRERBB2RAF1 | |
| SCHEMBL22188227 | 0.71 | PDGFRA (0.45) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3906234-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | Array BioPharma Inc. (US) | 2021-11-10 | — | — | EP | disclosed |
| CN-113302188-A | Quinoline compounds as TAM and MET kinase inhibitors | 阵列生物制药公司 | 2021-08-24 | — | — | CN | disclosed |
| WO-2020141470-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | ARRAY BIOPHARMA INC. (US) | 2020-07-09 | — | — | WO | disclosed |
| US-20200216416-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | ARRAY BIOPHARMA INC. (US) | 2020-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200216416-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | RET, MET, MERTK | SRC 36/4885MAP2K1 528/4885EGFR 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.